Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Down 87.8% in August

Silexion Therapeutics Corp (NASDAQ:SLXN) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 14,501 shares, a decline of 87.8% from the August 15th total of 119,287 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 257,490 shares, the short-interest ratio is currently 0.1 days.

Silexion Therapeutics Trading Down 14.8%

NASDAQ SLXN traded down $0.06 on Friday, hitting $0.36. The company’s stock had a trading volume of 1,965,385 shares, compared to its average volume of 1,009,246. The firm has a market cap of $2.00 million, a P/E ratio of -0.01 and a beta of -0.36. Silexion Therapeutics has a 52-week low of $0.34 and a 52-week high of $46.94. The company’s 50-day simple moving average is $1.44 and its 200 day simple moving average is $6.26.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($21.20) by $16.03. On average, research analysts forecast that Silexion Therapeutics will post -45.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Monday, June 15th. Maxim Group downgraded Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.